Biotech companies are about the riskiest investment someone can find in the stock market. They are often small, cash-strapped, and have a future inextricably tied to the success or failure of one clinical trial. For every Amgen , which has gone from a market cap of less than $1 billion 30 years ago to $147 billion today, there are hundreds that fade into obscurity. Yet, when they make it big, the rewards can be life-changing.
That's why Frequency Therapeutics (NASDAQ: FREQ) , Axsom Therapeutics (NASDAQ: AXSM) , and Trillium Therapeutics (NASDAQ: TRIL) are interesting. Each stock has been beaten down but has the potential to inflate shareholders' portfolios if their science proves successful.
For further details see:
3 Biotech Stocks That Could Be Millionaire-Makers